Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody.
about
Small and Innovative Molecules as New Strategy to Revert MDRDetailed characterization of cysteine-less P-glycoprotein reveals subtle pharmacological differences in function from wild-type proteinOncologic trogocytosis of an original stromal cells induces chemoresistance of ovarian tumoursSynthesis of a dual functional anti-MDR tumor agent PH II-7 with elucidations of anti-tumor effects and mechanismsTuning the drug efflux activity of an ABC transporter in vivo by in vitro selected DARPin bindersThe strong in vivo anti-tumor effect of the UIC2 monoclonal antibody is the combined result of Pgp inhibition and antibody dependent cell-mediated cytotoxicityThe Metastatic Potential and Chemoresistance of Human Pancreatic Cancer Stem CellsNeoadjuvant chemotherapy induces expression levels of breast cancer resistance protein that predict disease-free survival in breast cancerTargeting multidrug resistance in cancerCharacterization of conformation-sensitive antibodies to ADAMTS13, the von Willebrand cleavage proteaseMultidrug resistance in oncology: diagnostic and therapeutic approaches.Studies of human MDR1-MDR2 chimeras demonstrate the functional exchangeability of a major transmembrane segment of the multidrug transporter and phosphatidylcholine flippaseIn silico structure-based screening of versatile P-glycoprotein inhibitors using polynomial empirical scoring functions.Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs.Retrovirus-mediated multidrug resistance gene (MDR1) overexpression inhibits chemotherapy-induced toxicity of granulosa cells.The role of drug efflux pumps in acute myeloid leukemia.Cell biological mechanisms of multidrug resistance in tumors.Conformational analysis of human ATP-binding cassette transporter ABCB1 in lipid nanodiscs and inhibition by the antibodies MRK16 and UIC2.Improving cancer chemotherapy with modulators of ABC drug transporters.A new method for a quantitative assessment of P-glycoprotein-related multidrug resistance in tumour cells.Targeting of multidrug-resistant human ovarian carcinoma cells with anti-P-glycoprotein antibody conjugates.Molecular diagnosis of ATP-binding cassette transporter-related diseases.The multidrug resistance phenotype confers immunological resistance.A physiologic function for p-glycoprotein (MDR-1) during the migration of dendritic cells from skin via afferent lymphatic vesselsMDR1 synonymous polymorphisms alter transporter specificity and protein stability in a stable epithelial monolayer.P-glycoprotein function involves conformational transitions detectable by differential immunoreactivity.A single active catalytic site is sufficient to promote transport in P-glycoproteinFunctional intracellular P-glycoprotein.Treatment resistance mechanisms of malignant glioma tumor stem cellsRole of multidrug transporters in neurotherapeuticsP-glycoprotein confers methotrexate resistance in 3T6 cells with deficient carrier-mediated methotrexate uptake.Nanomedicinal strategies to treat multidrug-resistant tumors: current progress.Reversal of ATP-binding cassette drug transporter activity to modulate chemoresistance: why has it failed to provide clinical benefit?The role of P-glycoprotein in drug resistance in multiple myeloma.The ability of molecular docking to unravel the controversy and challenges related to P-glycoprotein--a well-known, yet poorly understood drug transporter.Molecular mechanisms of drug resistance and its reversal in cancer.The importance of drug transporters in human pluripotent stem cells and in early tissue differentiation.E-cadherin increasing multidrug resistance protein 1 via hypoxia-inducible factor-1α contributes to multicellular resistance in colorectal cancer.Cysteines introduced into extracellular loops 1 and 4 of human P-glycoprotein that are close only in the open conformation spontaneously form a disulfide bond that inhibits drug efflux and ATPase activity.Transfected MDCK cell line with enhanced expression of CYP3A4 and P-glycoprotein as a model to study their role in drug transport and metabolism.
P2860
Q27012455-9CC48F4D-1600-46DE-8462-5B8726F15AF0Q28366017-91E800A3-C24C-4F5F-A6D1-481B22252AE3Q28474331-E7EF0454-9582-4DFD-BBF3-A6D4A92690F3Q28481389-05D8F65F-E980-4077-A21A-B256B45FC230Q28484084-2F6874CA-859D-4712-8748-836A49F932CBQ28543104-5D3712A6-3535-4266-A6AD-DE0CD083080AQ28550040-08204034-74A9-45FA-AE8B-154049AFF62BQ28706276-8B382513-5000-47FE-89EC-130DB86E54E6Q29616803-9530A314-3632-41E8-AB10-304E900F1788Q33490606-7A7B0513-E3E4-46D0-A0AB-A9A3D40006E4Q33650232-990302EB-5014-46F2-9252-F3345D37A64DQ33869318-C4B68944-CC81-47B3-955E-C52FEA884401Q34414201-3104633E-0E8E-4CED-B961-89529F9C0961Q34448305-19B3CA57-714F-4A65-8993-0957B406E99FQ34726096-884F029D-207A-4757-BFBB-6A95C3B19609Q34769834-71903F2B-8A35-491D-A043-663920927F97Q35179585-91B35586-79B5-4CA4-9730-7AC15C2CFC59Q35604412-CC649FD4-FF63-4D4D-87DC-FBD85CB4F151Q36108251-E188681A-6E55-44AB-8115-9A66132F4AA9Q36134307-A4959283-7D0E-4575-9D70-DA75A382047DQ36185372-A9F13E42-A410-4F30-AC12-7A0B6A726891Q36252201-F71075C4-5D53-477D-99A3-3FBCA1B43C38Q36366884-2830B1B0-CE54-4AA4-AB9E-CB3D9C668D73Q36499151-B6D1B127-B6B0-4232-B408-0AA54B99B9D0Q36669409-60F86D88-83C3-4860-B447-A9DCF6E4622AQ36712329-A6BE7C84-B7DC-43EF-9BB6-66AABB9327A7Q36840944-815A2B07-C9D2-4F17-90DF-70705D3258AAQ36897086-52E88C9B-2601-4FFD-B0F9-5BD43CE917BDQ37129807-515C7244-D768-42CC-A48A-334396040178Q37689499-78475BBF-6BD6-4A5A-90B3-60C6CDD6C986Q37735490-E09F58FA-7C30-4A84-B3D3-899305826AB3Q37763152-210B34F2-FD61-48E0-960F-4A0E75BA70F7Q38055067-1F5D2DF3-E34A-4955-A5D1-122657CA3E6AQ38200143-C5BDAAD0-69B9-4C93-9BDB-502FF8231606Q38205719-D510E066-6714-4C02-8DA1-C3E97CDCC1BFQ38372575-778AC43D-9EC3-4671-BE89-F9B84490B7A2Q38642449-97509BC5-17B0-4C14-A32D-A5DEBF9C1CD5Q38848488-7E9120F7-91E3-4EB9-B8E9-AD73F4FB8522Q38972586-93754271-BDBC-488C-9D91-E49B710CC0F8Q39335333-01A42362-478A-4132-AE6F-55D3B73A0A8D
P2860
Efficient inhibition of P-glycoprotein-mediated multidrug resistance with a monoclonal antibody.
description
1992 nî lūn-bûn
@nan
1992 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1992 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1992年の論文
@ja
1992年論文
@yue
1992年論文
@zh-hant
1992年論文
@zh-hk
1992年論文
@zh-mo
1992年論文
@zh-tw
1992年论文
@wuu
name
Efficient inhibition of P-glyc ...... ce with a monoclonal antibody.
@ast
Efficient inhibition of P-glyc ...... ce with a monoclonal antibody.
@en
type
label
Efficient inhibition of P-glyc ...... ce with a monoclonal antibody.
@ast
Efficient inhibition of P-glyc ...... ce with a monoclonal antibody.
@en
prefLabel
Efficient inhibition of P-glyc ...... ce with a monoclonal antibody.
@ast
Efficient inhibition of P-glyc ...... ce with a monoclonal antibody.
@en
P2860
P356
P1476
Efficient inhibition of P-glyc ...... ce with a monoclonal antibody.
@en
P2093
E B Mechetner
I B Roninson
P2860
P304
P356
10.1073/PNAS.89.13.5824
P407
P577
1992-07-01T00:00:00Z